NY-UPTIME-INSTITUTE
30.7.2024 12:03:28 CEST | Business Wire | Press release
Uptime Institute today announced the release of its 14th Annual Global Data Center survey. The increased demand for digital services with both volume and compute intensity is challenging the power and cooling capabilities of much of the existing infrastructure. To meet the rising demand, data center operators and their IT clients are both investing and innovating more in their IT services and facilities and using external services. The effectiveness and impact of these investments will serve to shape the industry in the years ahead.
“Our data shows operators poised for major changes ahead on multiple levels,” said Andy Lawrence, executive director of research, Uptime Intelligence. “In 2024, we see the challenges of increased demand impacting power and cooling capabilities of existing facilities and the need for further investment to keep up with the demand. At the same time the industry needs to focus on continued staffing challenges to match capacity growth. And regulatory requirements are here and cannot be dismissed.”
Now in its 14th year, Uptime Institute’s annual survey remains the most comprehensive and longest-running study of its kind. The findings of this report highlight the practices and experiences of data center owners and operators in the areas of resiliency, sustainability, efficiency, staffing, cloud and artificial intelligence. It provides detailed insights into the digital infrastructure landscape and a view into its future trajectory. Key findings from the 2024 report include:
- Fewer than one half of data center owners and operators are tracking the metrics needed to assess their sustainability and/or meet pending regulatory requirements.
- Most operators recognize the benefits of AI and its potential. But despite many operators planning to host the technology, trust in AI for use in data center operations has declined for the third year in a row.
- The frequency and severity of data center outages remain mainly unchanged from 2023 or show small improvements. Operators are countering increases in complexity, density and extreme weather with investment and good management practices.
- Average server rack densities are increasing but remain below 8 kilowatts (kW). Most facilities do not have racks above 30kW, and those that do have only a few. This is expected to change in coming years.
- Enterprises continue to meet their IT needs with hybrid architectures. More than one half of workloads (45%) are now off-premises, continuing the gradual trend of recent years. Many continued to maintain their own data centers.
- Staffing challenges have neither improved nor worsened from 2023. More effort is needed to expand labor pools and skillsets to match the pace of capacity growth.
- Average PUE levels remain mostly flat for the fifth consecutive year, but this conceals advances in newer, larger facilities.
About the Survey:
Uptime conducted this year’s annual Global Data Center Survey online and by email in the first half of 2024. The survey participants represent a wide range of industry verticals in multiple countries. Responses were collected from a total of 879 end users registered for the survey and answered at least one question. More than one half are located in North America and Europe. Approximately one third of respondents work for professional IT/data center service providers (staff with operational or executive responsibilities for a third-party data center), such as those offering colocation, wholesale, software or cloud computing services.
Learn More:
Download the executive summary report here and register for the webinar here covering key trends and takeaways from the survey results on July 31st at 9:00 AM PDT (9:00 AM PDT, 12:00 PM EDT, and 5:00 PM BST). To join our Uptime Institute Bright Talk Channel, go to https://www.brighttalk.com/join/.
About Uptime Institute
Uptime Institute is the Global Digital Infrastructure Authority. With over 3,500 awards issued in over 118 countries around the globe, and over 1,000 currently active projects in 80+ countries, Uptime has helped tens of thousands of companies optimize critical IT assets while managing costs, resources, and efficiency.
For over 30 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their individual business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. Offerings include the organization’s Tier Standard and Certifications, Management & Operations reviews and assessments including SCIRA-FSI financial sector risk assessment, the Sustainability Assessment and a broad range of additional risk management, performance, availability, and related offerings. Uptime Education training programs have been successfully completed by over 90,000 data center professionals, expanded by the acquisition of CNet Training, Ltd.
Uptime Institute is headquartered in New York, NY, with main offices in London, Sao Paulo, Dubai, Riyadh, Singapore, and Taipei, and full-time Uptime professionals based in over 34 countries around the world. For more information, please visit uptimeinstitute.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730874079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
